

## Inspire Health Partners, LLC 2017 Primary Care Incentive Scorecard Specifications

Inspire is a community-based provider network that ensures patients get the right care, at the right time, in the right setting, in the most cost-effective manner. We are a collaboration between physicians, hospitals and area employers who are working together to improve population health, deliver a better patient experience, and provide more affordable care.

## **Table of Contents**

Table of Contents	2
Prev: ACO #42 - Statin Therapy	3
Prev: HEDIS - Colorectal Cancer Screening	3
CAD: Antiplatelet Therapy	4
DM: HEDIS - HbA1c Poor Control (>9)	4
DM: HbA1c Testing (1/yr)	4
DM: HEDIS -Medical Attention for Nephropathy	5
HTN: HEDIS - BP Control	6
Imm: HEDIS (CIS) - Childhood Immunization Status	6
Imm: HPV Vaccination	7
Prev: HEDIS (W15) - Well-Child Visit (6)	7
Physician Engagement	8
30 Day All Cause Readmission Rate	8
Mortality Index	8
Patient Satisfaction	8

Measure	Description	Specifications	Target	Data Source
Prev: ACO #42 - Statin Therapy Individual Performance	Percentage of patients who are high risk for cardiovascular events who are actively taking a statin medication.	Numerator- Patients in the denominator who are actively taking a statin medication.	60%	Phytel
		Denominator- Patients included in any of the following:  ∘ Adults aged ≥ 21 years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerosis cardiovascular disease (ASCVD)  OR  ∘ Adults aged ≥ 21 years with a fasting or direct low-density lipoprotein cholesterol (LDL-C) level ≥ 190 mg/dL  OR  ∘ Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL. with the EXCLUSION of patients with documented allergies or other contraindications		
Measure	Description	Specifications		Data Source
Prev: HEDIS - Colorectal Cancer Screening Individual Performance	Prev: HEDIS - Colorectal Percentage of patients who are currently 51-75 of age, except those		61%	Phytel

Measure	Description	Specifications	Target	Data Source
Coronary Artery Disease CAD: Antiplatelet Therapy Individual Performance	atelet Therapy with a diagnosis of coronary artery Patients in the denominator currently taking		89%	Phytel
Measure	Description	Specifications	Target	Data Source
DM: HEDIS - HbA1c Poor Control (>9%) (within last 1 year) Individual Performance	Percentage of patients 18-75 years of age whose most recent HbA1c level is >9% or who did not have the test performed	Numerator Patients in the denominator whose most recent HbA1c >9% OR test not performed in the last 12 months Denominator: Patients aged 18-75 years who had - at least two outpatient visits, observation visits, ED visits, or non- acute inpatient encounters with diabetes listed as a diagnosis during the last 24 months OR - at least one acute inpatient encounter with diabetes listed as a diagnosis during the last 24 months OR - diabetes listed as an ACTIVE problem in the problem list with the EXCLUSION of patients who have a diagnosis of steroid induced diabetes (SIDM) or gestational diabetes (GDM) and do not have any diagnosis of diabetes in any setting during the last 24 months	24%	Phytel
Measure	Description	Specifications	Target	Data Source
Diabetes- DM: HbA1c Testing (1/yr)  Individual Performance  Percentage of patients ≥ 18 who had one HbA1c test performed during the last 12 months		Numerator: Patients who had one HbA1c test documented during the last 12 months  Denominator: Patients aged 18 years and older who had - at least two outpatient visits, observation visits, ED visits, or nonacute inpatient encounters with diabetes listed as a diagnosis during the last 24 months OR - at least one acute inpatient encounter with diabetes listed as a diagnosis during the last 24 months OR - diabetes listed as an ACTIVE problem in the problem list with the EXCLUSION of patients who have a diagnosis of steroid induced diabetes (SIDM) or gestational diabetes (GDM) and	91%	Phytel

Measure	Description	do not have any diagnosis of diabetes in any setting during the last 24 months.  Specifications	Target	Data
Diabetes: DM: HEDIS - Medical Attention for Nephropathy  Individual Performance	Percentage of diabetic patients who have evidence of nephropathy or received a nephropathy screening test	Numerator Patients in the denominator with at least one of the following: - ESRD, chronic kidney disease, or kidney transplant - currently taking an ACE/ARB medication - a positive dipstick protein test during the last 12 months - microalbumin or other nephropathy screening test performed during the last 12 months Denominator: Patients aged 18-75 years who had - at least two outpatient visits, observation visits, ED visits, or nonacute inpatient encounters with diabetes listed as a diagnosis during the last 24 months OR - at least one acute inpatient encounter with diabetes listed as a diagnosis during the last 24 months OR - diabetes listed as an ACTIVE problem in the problem list with the EXCLUSION of patients who have a diagnosis of steroid induced diabetes (SIDM) or gestational diabetes (GDM) and do not have any diagnosis of diabetes in any setting during the last 24 months	88%	Source Phytel

Measure	Description	Specifications		Data Source
HTN: HEDIS - BP Control Individual Performance	BP Control The percentage of individuals 18-85 Numerator:		71%	Phytel
Measure	Description	measurement year  Specifications	Target	Data Source
Imm: HEDIS (CIS) - Childhood Immunization Status	The percentage of children 2 years of age who have had four diphtheria, tetanus, and acellular pertussis (DTaP); three polio (IPV); one measles, mumps, and rubella (MMR); three haemophilus influenza type B (HiB); three hepatitis B (HepB); one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (HepA); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday.	Numerator Patients who have completed the required doses for all vaccinations in Combination 10 (DTaP, IPV, MMR, HiB, HepB, VZV, PCV, HepA, RV, Influenza) Denominator: All children aged ≥2 years, with the exclusion of children with: 1. Anaphylactic reaction to vaccine 2. Encephalopathy with a vaccine adverse-effect code 3. Immunodeficiency 4. HIV 5. Lymphoreticular cancer, multiple myeloma, or leukemia 6. Anaphylactic reaction to neomycin, streptomycin, polymixin B, or common baker's yeast	48%	Phytel
Measure	Description	Specifications	Target	Data Source
Imm: HPV Vaccination Individual Performance	The percentage of females 11 to 26 years and males 11 to 21 years who completed the HPV vaccination series or are on schedule for the HPV series.	Numerator:  Patients ≥11 yrs to <15 years who received at least 2 doses of HPV vaccine OR  Patients ≥11 yrs to <27 years who received at least 3 doses of HPV vaccine OR  Patients ≥11 yrs to <27 years who received ≥ 1 dose, require a 2nd dose, but are schedule based on minimum required interval between doses (6 months) OR	24%	Phytel

Magazza	Description	doses, require a 3rd dose, but are on schedule based on minimum required interval between doses (6 months).  Denominator:  - Females ages ≥11 yrs to <27 years  - Males ages ≥11 yrs to <22 years  with the exclusion of pregnant females or pts with documented status of vaccine "deferred", or with allergy to the vaccine or its components, or with history of adverse reaction to HPV vaccine or patient who declined the vaccination.  Specifications	Toward	Data
Measure	Description	Specifications	Targe t	Source
Prev: HEDIS (W15) - Well- Child Visit (6)	+ The percentage of patients who turned 15 months old in the last 12 months and who had ≥ 6 well-child visits during their first 15 months of life.	Patients in the denominator who had ≥ 6 visits during the first 15 months of life Denominator:  Patients who turned 15 months within the last 12 months	85%	Phytel/ EMR/ SIHO
Measure	Description	Specifications	Target	Data Source
Physician engagement (meeting/educational session attendance) Individual Performance	Physicians that attend meeting or educational sessions defined by Inspire Health Partners (IHP) as being a qualifying IHP engagement event	Numerator- Individual Physician attendance at meeting or educational session defined by Inspire Health Partners (IHP) as being a qualifying IHP engagement or event Denominator- Inspire Health Partners (IHP) defined engagement or event	50%	IHP

Measure	Description Specifications		Target	Data Source
30 day all cause readmission rate  Group Performance	Patients that have an Inpatient readmission within 30 days of the discharge from an Inpatient hospitalization  For CRH measurement, the inclusions and exclusions have been manually defined to match the algorithm of the software used by SMC	Numerator- Patients that had an Inpatient to Inpatient readmission with the following  EXCLUSIONS: all patients with a discharge disposition of Hospice Patients with DRG's for Dialysis, C-Section, Vaginal Delivery, Chemotherapy, Radiotherapy, Rehab Patients with a Major Diagnostic Category (MDC) of Mental Health Disease, Alcohol Related Mental Health Disease All IP Rehab patients All Mental Health patients All patients that had a discharge disposition of AMA All patients that had a discharge disposition to another acute care facility All expired patients All pregnant patients NOT yet delivered Denominator: All patients with the same exclusions listed above	Top Decile (Variable )	CRH-MIDAS SMC-UHC-Universit y HealthSy stem Consortiu m Will transition to Truven Mid-2015
Measure	Description	Specifications	Target	Data Source
Mortality index Group Performance	Patients that expired while an Inpatient in the hospital, specific to a defined date range	Numerator- The number of Patients that expire while Inpatient in the hospital for a specific date range  Denominator- All Inpatients, including Mental Health and Inpatient Rehab  EXCLUSIONS: - Skilled Nursing Facility, Long Term Care, Intermediate Care Facility, Hospice for a specific date range	Top Decile (Variable )	CRH-Sg2 SMC- UHC- Universit y HealthSy stem Consortiu m Will transition to Truven Mid-2015
Measure	Description	Specifications	Target	Data Source
Patient satisfaction (hospital- based; rolling 4 quarters) Group Performance	Patients satisfaction with the communication they received from their Physician while they were an Inpatient in the hospital	This measure is based on the patient's response to the following statements/questions:  - Doctors treat you with courtesy/respect  - Doctors listen carefully to you  - Doctors explain in a way you understand	Top Decile (Variable )	Press- Ganey

				::		
ī.		$\sim$	$\sim$	1	V	$\cap$
П	$\cap$	$\supset$	$\cup$	1	ı	ヒ
			1			

Please direct comments or inquiries to:

Marc Rothbart at <a href="mrothbart@inspirehealthpartners.com">mrothbart@inspirehealthpartners.com</a>

OR

Hanadi Asfoor at <a href="mailto:hasfoor@inspirehealthpartners.com">hasfoor@inspirehealthpartners.com</a>

OR

Sheetal Prabhune at <a href="mailto:sprabhune@inspirehealthpartners.com">sprabhune@inspirehealthpartners.com</a>